Welcome : Guest

PROPHYLACTIC HUMAN VACCINES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Prophylactic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines, and Adult Prophylactic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 63 companies including many key and niche players such as -

ALK – Abelló A/S
Altimmune, Inc.
Bavarian Nordic A/S
BiondVax Pharmaceuticals Ltd.
Bharat Biotech International Limited

Click here to request a full list of companies covered in the report...

Code: MCP-1176
Price: $4950
Companies: 63
Pages: 358
Date: July 2016
Market Data Tables: 94
 



TABLE OF CONTENTS


  PROPHYLACTIC HUMAN VACCINES (Complete Report) Pages : 358   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Human Vaccines: A Prelude.....II-1
Human Vaccines Market – A Snapshot.....II-1
1$100
   Market Dynamics.....II-21$100
   Growth Drivers in a Capsule.....II-31$100
   Developed World: The Key Markets.....II-4
Emerging Markets: The Future Growth Area.....II-4
1$100
   Vaccine Pricing: The Developed – Developing Divide.....II-51$100
   Prophylactic Pediatric Vaccines – A Mature Market.....II-6
Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers.....II-6
1$100
   Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective
  Vaccines.....II-7
Novel Vaccines against Emerging Infectious Diseases.....II-7
Ongoing Developments for a Vaccine against Zika Virus.....II-7
1$100
   Sanofi’s Dengue Vaccine First-to-Market.....II-81$100
   Pipeline & Marketed Dengue Vaccine: 2016.....II-91$100
   Computational Tools Come to Aid in Development of Ebola Vaccines.....II-10
Vaccine for AIDS.....II-10
Ongoing Research for HIV Vaccine & Commercial Pipeline.....II-10
1$100
   List of Clinical Trial (Phase II) AIDS Vaccines: 2015.....II-111$100
   Staggering Global Statistics of AIDS – Opportunity Indicator.....II-12
Table 1: HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart).....II-12
1$350
   Table 2: Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart).....II-131$350
   Table 3: Worldwide AIDS related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart).....II-14

Table 4: HIV-Positive Individuals, by Gender (2014): Percentage Breakdown of Women and Men Tested HIV-Positive in all WHO Regions (includes corresponding Graph/Chart).....II-14
1$350
   Vaccination-Autism Link and Other Safety Concerns Thwarted.....II-15
Threat of Pandemic Rejuvenates Vaccine Market.....II-15
Influenza Vaccines on a Growing Spree.....II-15
1$100
   Influenza Vaccines on the Current Market: 2016.....II-16
H1N1 Vaccines Hit the Market in August 2009.....II-16
1$100
   H1N1 Influenza Vaccines and Manufacturers.....II-171$100
   Influenza Market Faces Several Challenges.....II-181$100
   Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal
  Vaccines Market.....II-19
2$200
   Unmet Demand for TB Vaccine.....II-211$100
   Key TB Vaccine Candidates in the Pipeline: 2016.....II-22
Need for a Human Vaccine for Leishmaniasis.....II-22
Economic Factors Hamper Optimal Vaccine Development and Delivery.....II-22
Increasing Need for Vaccine Promotion in the Developing Regions.....II-22
1$100
   Changing Vaccine Needs.....II-23
Religious Concerns over Immunizing Young Girls against Human Papillomavirus.....II-23
Changing Travel Patterns Increase Demand for Hepatitis B Vaccine.....II-23
DNA Vaccines: Engineering Growth.....II-23
2$200
   Noninjectable Vaccines: Gain without Pain.....II-25
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines.....II-25
1$100
   Conjugate Vaccines: A Technological Innovation.....II-26
Hib Vaccines on the Market: 2016.....II-26
1$100
   Growing Pricing Pressure – A Major Market Deterrent.....II-27
Safety Issues Come to the Fore.....II-27
BioWarfare: Threat Perception and Preparedness.....II-27
1$100
   Overview of Potential Bio-Terrorist Agents.....II-28
Smallpox (Variola Major).....II-28
Anthrax (Bacillus Anthracis).....II-28
1$100
   Plague (Yersinia Pestis).....II-29
Botulism (Clostridium Botulinum).....II-29
Tularemia (Francisella Tularensis).....II-29
Tackling Cold Chain Issues.....II-29
1$100
   Trade Statistics.....II-30
Table 5: Global Exports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart).....II-30
1$350
   Table 6: Global Imports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart).....II-311$350
   Competitive Scenario.....II-32
Leading Players.....II-32
1$100
   Table 7: Leading Players in the Global Human Vaccines Market (2015): Annual Sales in US$ Million for GlaxoSmithKline, Merck, Pfizer and Sanofi (includes corresponding Graph/Chart).....II-331$350
   Table 8: Top Five Human Vaccines Worldwide by Sales Value: 2015 (In US$ Million) (includes corresponding Graph/Chart).....II-34
Pfizer Scores Big with Prevnar.....II-34
1$350
   Trumenba Shows Promise in Phase III Clinical Trials.....II-35
GSK Takes Big Leap into the Meningococcal Vaccine Market.....II-35
1$100
   Acquired Products Strengthen GSK’s Vaccines Sales.....II-36
The Potential for MenABCWY Vaccine.....II-36
1$100
   Table 9: US Meningococcal Disease Incidence by Serogroup Distribution (1990 & 2013): Percentage Breakdown of Disease Incidence for Serotypes B, C, Y and Others (includes corresponding Graph/Chart).....II-37
Sanofi Works on Production Issues to Boost Sales.....II-37
1$350
   New Vaccines to Enhance Prospects for Sanofi.....II-38
Sanofi’s Human Vaccine R&D Pipeline.....II-38
1$100
   Weaker Sales Drive Merck and Sanofi’s European JV Split.....II-39
Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market.....II-39
1$100
   Introduction to the Concept of Immunity.....II-40
Role of Vaccines in Strengthening the Immune System.....II-40
1$100
   Vaccines and Immunotherapy.....II-41
Historical Overview of Vaccines.....II-41
How it Began.....II-41
1$100
   So Far So Good.....II-421$100
   Successful Vaccine Introductions in the Past.....II-43
Contribution of Animal Research to Vaccine Production.....II-43
1$100
   Types of Vaccines.....II-44
Live, Attenuated Vaccines.....II-44
1$100
   Combination Vaccines.....II-45
Killed or Inactivated Vaccines.....II-45
1$100
   DNA & Recombinant DNA Vaccines.....II-461$100
   Toxoids.....II-47
Cellular Fractions.....II-47
Conjugate Vaccines.....II-47
Subunit Vaccines.....II-47
1$100
   Passive Immunization.....II-48
Prophylactic Vaccines.....II-48
Prevention Better than Cure.....II-48
Prophylactic Pediatric Vaccines.....II-48
Vaccination over the Years.....II-48
1$100
   BCG Vaccine.....II-49
Growth Boosting Factors for TB Vaccines.....II-49
Demand Restraining Factors for TB Vaccines.....II-49
1$100
   Major Issues to be addressed in the TB Vaccine Market.....II-50
Hemophilus Influenza Type B Vaccine.....II-50
Diphtheria/Tetanus/Pertussis Vaccines.....II-50
Hepatitis A Vaccine.....II-50
Hepatitis B Vaccine.....II-50
1$100
   Hepatitis B Epidemiology.....II-51
Measles/Mumps/Rubella Vaccines.....II-51
Rotavirus Vaccines.....II-51
Polio Vaccines.....II-51
1$100
   Varicella Vaccine.....II-52
Combination Vaccines.....II-52
1$100
   Prophylactic Adult Vaccines.....II-53
Hepatitis A Vaccine.....II-53
1$100
   Hepatitis B Vaccines.....II-541$100
   Key Issues Affecting the Adult Hepatitis Vaccines Market.....II-55
Cholera Vaccine.....II-55
Japanese Encephalitis Vaccines.....II-55
1$100
   Influenza Vaccines.....II-56
Influenza A Virus.....II-56
Influenza A (H1N1) Virus.....II-56
1$100
   Vaccine Virus Selection for the 2015-2016 Influenza Season.....II-57
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern
  Hemisphere for 2015-2016.....II-57
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern
  Hemisphere for 2015-2016.....II-57
1$100
   Lyme Disease Vaccine.....II-58
Pneumococcal Disease Vaccines.....II-58
1$100
   Meningococcal Vaccines.....II-59
Rabies Vaccines.....II-59
1$100
   Typhoid Vaccine.....II-60
Yellow Fever Vaccine.....II-60
Mechanisms for Vaccine Delivery.....II-60
Edible Vaccines.....II-60
2$200
   Oral Vaccines.....II-62
Tablet Based Vaccines.....II-62
Mucosal Delivery.....II-62
Transdermal Patch Delivery.....II-62
Storage Problems.....II-62
1$100
   Perfluorocarbons as Alternative to Overcome Storage Problems.....II-63
Costs.....II-63
Standards for Vaccine Safety and Quality.....II-63
1$100
   Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine.....II-64
Takeda Begins Phase2b Trial for World’s First Norovirus Vaccine.....II-64
Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine.....II-64
Investigational Vaccine for P.vivax Malaria Enters Human Trials.....II-64
Valneva Reports Postive Phase 2 Results for Vaccine Candidate against
  C.difficile.....II-64
Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein
  Vaccine.....II-64
1$100
   Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine.....II-65
Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate
  into Clinical Studies.....II-65
Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial.....II-65
1$100
   FDA Approves 2016/17 Formulation of Protein Sciences Corporation’s Flublok.....II-66
Sanofi’s Dengue Vaccine Approved in Costa Rica.....II-66
GSK Supplies Flu Vaccines based on Valneva’s EB66 Cell Line.....II-66
FDA Approves Seqirus’ FLUCELVAX QUADRIVALENT™ Influenza Vaccine.....II-66
China Launches HFMD Vaccine.....II-66
Bharat Biotech Introduces ZIKAVAC® Vaccine for Zika Infection.....II-66
Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection.....II-66
1$100
   WHO Accepts Merck’s Investigational Ebola Vaccine Application for Review.....II-67
Sanofi’s Dengvaxia® Receives Marketing Authorization in Mexico.....II-67
SK Chemicals Launches Influenza Vaccine SKYCellflu.....II-67
Sanofi Pasteur Ships First Doses of Fluzone® for the US Market.....II-67
Bharat Biotech Launches Made-in-India ROTAVAC® Vaccine.....II-67
FDA Approves Sanofi’s sBLA for Fluzone Vaccine.....II-67
FDA Approves Merck’s HPV Vaccine GARDASIL®9.....II-67
1$100
   Sanofi Pasteur Launches Shan5™ Vaccine Developed by its Affiliate Shantha.....II-68
US FDA Approves First Meningococcal Disease Vaccine Trumenba.....II-68
1$100
   WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer’s Prevnar
  13.....II-69
Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics’
  Facility.....II-69
Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government.....II-69
Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines.....II-69
WHO Recommends Sanofi’s Dengvaxia in Nations with Widespread Dengue.....II-69
Kaketsuken to Sell Vaccines Business to Astellas.....II-69
1$100
   Sanofi and Merck End Joint Venture on Vaccines.....II-70
GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine.....II-70
Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA.....II-70
Bavarian Nordic Enters into License Agreement with Janssen.....II-70
CSL Rebrands Influenza Vaccines Business as Seqirus.....II-70
MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine
  R&D.....II-70
1$100
   GlaxoSmithKline Acquires Novartis’ Vaccines Business.....II-71
Vaxin Changes Name to Altimmune.....II-71
Takeda Expands Commercialization Agreement with Nanotherapeutics.....II-71
MedImmune Enters Into License Agreement with Inovio Pharmaceuticals.....II-71
CSL Completes Acquisition of Novartis’ Influenza Vaccines Business.....II-71
Pfizer to Acquire Meningitis Vaccines from GSK.....II-71
Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew
  License.....II-71
Takeda Transfers HPV Vaccine License Agreement to Kaketsuken.....II-71
1$100
   GlaxoSmithKline Acquires GlycoVaxyn.....II-72
Pfizer Acquires Redvax GmbH.....II-72
Pfizer Acquires Baxter’s Vaccines and Portion of Manufacturing Facility.....II-72
1$100
   ALK – Abelló A/S (Denmark).....II-73
Altimmune, Inc. (US).....II-73
Bavarian Nordic A/S (Denmark).....II-73
1$100
   BiondVax Pharmaceuticals Ltd. (Israel).....II-74
Bharat Biotech International Limited (India).....II-74
GlaxoSmithKline Plc. (UK).....II-74
1$100
   Hualan Biological Engineering Inc. (China).....II-75
Janssen Pharmaceuticals, Inc. (US).....II-75
1$100
   MedImmune (US).....II-76
Merck & Co., Inc. (US).....II-76
Pfizer Inc. (US).....II-76
1$100
   Sanofi Pasteur SA (France).....II-771$100
   Serum Institute of India Pvt. Ltd. (India).....II-78
Shanghai BravoBio Co., Ltd. (China).....II-78
Seqirus (UK).....II-78
1$100
   SK Chemicals Co., Ltd. (Korea).....II-79
Takeda Pharmaceutical Company Limited (Japan).....II-79
Zydus Cadila (India).....II-79
2$200
   Table 10: World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines Prophylactic by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-811$350
   Table 11: World Historic Review for Prophylactic Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-821$350
   Table 12: World 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-831$350
   Table 13: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-841$350
   Table 14: World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-851$350
   Table 15: World 14-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-861$350
   Table 16: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....II-871$350
   Table 17: World Historic Review for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....II-881$350
   Table 18: World 14-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....II-891$350
   A. Market Analysis.....III-1
Outlook.....III-1
Key Growth Drivers.....III-1
Select Market Constraints.....III-1
Major Trends in the US Vaccines Development.....III-1
Increasing Consolidation Activity among Companies.....III-1
1$75
   Combination Vaccines and New Delivery Models Gaining Traction.....III-2
Protests against Vaccination Make Companies More Cautious.....III-2
Technological Challenges in the Development of RSV Vaccines.....III-2
1$75
   Pediatric Vaccines Market.....III-3
Improved Pricing Scenario for Pediatric Vaccines.....III-3
Market Focus Shifting from Pediatric Vaccines.....III-3
Growth Drivers for US Pediatric Vaccines Market.....III-3
1$75
   Demand Restraining Factors for US Pediatric Vaccines Market.....III-4
Opportunity Indicators.....III-4
Table 19: Number of Reported Cases for Vaccine-Preventable Diseases in American Regions: 2009-2013.....III-4
1$200
   Table 20: Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-5
The US Influenza Vaccine Market.....III-5
‘Swine Flu’ Strain Returns in the 2013-14 Season.....III-5
1$200
   Table 21: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016.....III-61$200
   Table 22: CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016.....III-7
A Background on the Need for Flu Vaccines.....III-7
1$200
   Need for Immunization Schedule for Adults.....III-8
Vaccines and Intended User Group.....III-8
1$75
   Adult Population: To Drive Future Growth of Pertussis Vaccines Market.....III-9
Table 23: Pertussis Cases (In Thousands) for Years 2000 through 2014 (includes corresponding Graph/Chart).....III-9
Vaccine Pricing in the US.....III-9
1$200
   Regulatory Environment.....III-10
Review Process Make Vaccines Safer.....III-10
Imports-Exports Scenario.....III-10
1$75
   Table 24: US Exports of Human Vaccines by Country (2014 & 2015) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart).....III-111$200
   Table 25: US Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart).....III-121$200
   Clinical Trials.....III-131$75
   Product Launches.....III-14
Strategic Corporate Developments.....III-14
2$150
   Select Players.....III-164$300
   B. Market Analytics.....III-20
Table 26: US Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-20
1$200
   Table 27: US Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-211$200
   Table 28: US 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-221$200
   A. Market Analysis.....III-23
Outlook.....III-23
Opposition to CMA’s Mandatory Vaccination Program.....III-23
2009 H1N1 Pandemic Boosts Vaccines Sales.....III-23
1$75
   Trade Statistics.....III-24
Table 29: Canadian Exports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart).....III-24
1$200
   Table 30: Canadian Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart).....III-251$200
   B. Market Analytics.....III-26
Table 31: Canadian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-26
1$200
   Table 32: Canadian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-271$200
   Table 33: Canadian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-281$200
   A. Market Analysis.....III-29
Outlook.....III-29
Controversy, Confusion and Hasty Actions Marr HPV Vaccination Market.....III-29
Strategic Corporate Developments.....III-29
1$75
   Key Japan-based Player – Takeda Pharmaceutical Company Limited.....III-301$75
   B. Market Analytics.....III-31
Table 34: Japanese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-31
1$200
   Table 35: Japanese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-321$200
   Table 36: Japanese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-331$200
   A. Market Analysis.....III-34
Outlook.....III-34
Vaccine Pricing in Europe.....III-34
Major Drawbacks.....III-34
Regulatory Mechanism for Vaccines in Europe.....III-34
1$75
   An Insight into European Influenza Vaccination Scenario.....III-35
H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation.....III-35
Cell-based Vaccine Production Remains Nascent, Egg-based widely used.....III-35
EU Welcomes Quadrivalent LAIVs.....III-35
1$75
   Major Influenza Vaccines Available in European Union Member Countries.....III-36
Major H1N1 Flu Vaccines Available in Select East European Markets.....III-36
1$75
   B. Market Analytics.....III-37
Table 37: European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-37
1$200
   Table 38: European Historic Review for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-381$200
   Table 39: European 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-391$200
   Table 40: European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-401$200
   Table 41: European Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-411$200
   Table 42: European 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-421$200
   A. Market Analysis.....III-43
Outlook.....III-43
Clinical Trial.....III-43
Product Launches.....III-43
1$75
   Strategic Corporate Developments.....III-44
Key Players.....III-44
2$150
   B. Market Analytics.....III-46
Table 43: French Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-46
1$200
   Table 44: French Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-471$200
   Table 45: French 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-481$200
   Market Analysis.....III-49
Table 46: German Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-49
1$200
   Table 47: German Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-501$200
   Table 48: German 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-511$200
   Market Analysis.....III-52
Table 49: Italian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-52
1$200
   Table 50: Italian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-531$200
   Table 51: Italian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-541$200
   A. Market Analysis.....III-55
Outlook.....III-55
Product Launch.....III-55
Strategic Corporate Developments.....III-55
1$75
   Select Players.....III-561$75
   B. Market Analytics.....III-57
Table 52: UK Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-57
1$200
   Table 53: UK Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-581$200
   Table 54: UK 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-591$200
   Market Analysis.....III-60
Table 55: Spanish Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-60
1$200
   Table 56: Spanish Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-611$200
   Table 57: Spanish 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-621$200
   Market Analysis.....III-63
Table 58: Russian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-63
1$200
   Table 59: Russian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-641$200
   Table 60: Russian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-651$200
   A. Market Analysis.....III-66
Outlook.....III-66
Clinical Trial.....III-66
Strategic Corporate Developments.....III-66
1$75
   Select Players.....III-671$75
   B. Market Analytics.....III-68
Table 61: Rest of Europe Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-68
1$200
   Table 62: Rest of Europe Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-691$200
   Table 63: Rest of Europe 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-701$200
   A. Market Analysis.....III-71
Outlook.....III-71
Asian Vaccine Industry.....III-71
Challenges.....III-71
1$75
   2014-15: Deadliest Swine Flu Season in India Since 2009.....III-72
Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific
  Markets.....III-72
1$75
   B. Market Analytics.....III-73
Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-73
1$200
   Table 65: Asia-Pacific Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-741$200
   Table 66: Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-751$200
   Table 67: Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-761$200
   Table 68: Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-771$200
   Table 69: Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-781$200
   A. Market Analysis.....III-79
Outlook.....III-79
Large Population Offers High Potential.....III-79
Growth Drivers.....III-79
1$75
   China – A Lucrative yet Difficult to Permeate Market.....III-80
Product Launch.....III-80
1$75
   Strategic Corporate Development.....III-81
Key Players.....III-81
1$75
   B. Market Analytics.....III-82
Table 70: Chinese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-82
1$200
   Table 71: Chinese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-831$200
   Table 72: Chinese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-841$200
   A. Market Analysis.....III-85
Current & Future Analysis.....III-85
Market Overview.....III-85
Hepatitis B Vaccine in India.....III-85
1$75
   Combination Vaccines.....III-861$75
   Indian Vaccine Market – Select Combination Vaccines Available in the
  Country.....III-87
The Patent Act (Third Amendment), 2005.....III-87
Product Launches.....III-87
1$75
   Strategic Corporate Development.....III-88
Select Players.....III-88
3$225
   B. Market Analytics.....III-91
Table 73: Indian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-91
1$200
   Table 74: Indian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-921$200
   Table 75: Indian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-931$200
   A. Market Analysis.....III-94
Outlook.....III-94
Malaysia – Stricken by Vaccine Shortage.....III-94
Product Launches.....III-94
1$75
   Strategic Corporate Developments.....III-95
Key Korea-based Player – SK Chemicals Co., Ltd......III-95
1$75
   B. Market Analytics.....III-96
Table 76: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-96
1$200
   Table 77: Rest of Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-971$200
   Table 78: Rest of Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-981$200
   Market Analysis.....III-99
Table 79: Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-99
1$200
   Table 80: Latin American Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1001$200
   Table 81: Latin American 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-1011$200
   Table 82: Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-1021$200
   Table 83: Latin American Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1031$200
   Table 84: Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-1041$200
   Market Analysis.....III-105
Table 85: Brazilian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-105
1$200
   Table 86: Brazilian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1061$200
   Table 87: Brazilian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-1071$200
   A. Market Analysis.....III-108
Outlook.....III-108
Product Launches.....III-108
1$75
   B. Market Analytics.....III-109
Table 88: Rest of Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-109
1$200
   Table 89: Rest of Latin American Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1101$200
   Table 90: Rest of Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-1111$200
   A. Market Analysis.....III-112
Outlook.....III-112
Nigeria: A Severely Underserved Market.....III-112
Table 91: Deaths in Nigerian Children Under Five Years by Cause (2015): Percentage Breakdown of Number of Deaths due to Diarrhoea, Malaria, Measles, Neonatal, Pneumonia, and Others (includes corresponding Graph/Chart).....III-112
1$200
   BiondVax Pharmaceuticals Ltd. – A Key Israel-based Player.....III-113
B. Market Analytics.....III-113
Table 92: Rest of World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).....III-113
1$200
   Table 93: Rest of World Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).....III-1141$200
   Table 94: Rest of World 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).....III-1151$200
  
Total Companies Profiled: 63 (including Divisions/Subsidiaries - 72)

Region/Country Players

The United States 22 Canada 1 Japan 5 Europe 14 France 3 Germany 2 The United Kingdom 2 Spain 1 Rest of Europe 6 Asia-Pacific (Excluding Japan) 28 Latin America 1 Middle East 1
Click here to request a full table of contents and more details on this project.